Organon shares jump as Merck's new women's health spinoff posts strong start for biosims, infertility drugs

It’s been a mere two months since Merck’s women’s health spinoff Organon set off to chart its own path as an independent company. That hasn’t been an easy feat amid a global pandemic, but so far the fledgling drugmaker is delivering early results that are catching Wall Street’s attention.